![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Predictive modelling to identify and characterize fast progressors
among patients with non-alcoholic steatohepatitis (NASH)
|
|
|
EASL 2020 Aug27-29 virtual
B. Reinhart1, M. Docherty2, M-M. Balp3, S.A. Regnier3, A. Tietz3, J. Cai4, S. Porwal5, M.C. Pedrosa3, J.M. Schattenberg6
1ZS Associates, Zurich, Switzerland; 2ZS Associates, Philadelphia, USA; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Pharmaceuticals Inc, East Hanover, USA;
5ZS Associates, Pune, India; 6Universitätsmedizin Mainz, Mainz, Germany
![0908201](../images/090820/090820-3/0908201.gif)
![0908202](../images/090820/090820-3/0908202.gif)
![0908203](../images/090820/090820-3/0908203.gif)
![0908204](../images/090820/090820-3/0908204.gif)
![0908205](../images/090820/090820-3/0908205.gif)
![0908206](../images/090820/090820-3/0908206.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|